Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Anticancer research - 1 Sept 2014

Pagano Maria, Sierra Nuria Maria Asensio, Panebianco Michele, Rossi Giulio, Gnoni Roberta, Bisagni Giancarlo, Boni Corrado

Abstract excerpt

PURPOSE: To retrospectively evaluate sorafenib activity and safety in patients with metastatic thymic carcinoma (TC) and to correlate outcome with c-KIT and PDGFR-alpha mutational status. PATIENTS AND METHODS: Patients with metastatic thymic carcinoma treated with sorafenib after at least one pri...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Staging
Share to Niacinamide
Share to Phenylurea Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sorafenib

Share to Thymoma

Share to Thymus Neoplasms

Source

Identifiers

PMID: 25202099

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25202099-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.PMID 25202099Read ↗

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Semantic proximity Read ↗

Molecular markers for patients with thymic malignancies: not feasible at present?Semantic proximity Read ↗

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.Semantic proximity Read ↗

Do thymic malignancies respond to target therapies?Semantic proximity Read ↗

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.Semantic proximity Read ↗

Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.Semantic proximity Read ↗

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Semantic proximity Read ↗

Thymic epithelial tumors: From biology to treatment.Semantic proximity Read ↗

Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?Semantic proximity Read ↗

A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3Semantic proximity Read ↗

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).Semantic proximity Read ↗

Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.